What is Y-Mabs Therapeutics Inc Annual Revenue?

Y-Mabs Therapeutics Inc Annual Revenue rose 3.38%, in the last year to $87.68 M. Its sector's average revenue growth for the last fiscal year was 7.49%.

What is Y-Mabs Therapeutics Inc Annual Net Profit?

Y-Mabs Therapeutics Inc Annual Net Profit fell 38.45% in the last year to $29.67 M. Its sector's average net profit growth for the last fiscal year was -32.44%.

What is Y-Mabs Therapeutics Inc Price to Earning Ratio?

Y-Mabs Therapeutics Inc Price to Earning Ratio is -7.35, which is negative.

What is Y-Mabs Therapeutics Inc Stock Price?

Y-Mabs Therapeutics Inc Stock Price fell 68.14% and underperformed its sector by 74.95% in the past year.

What is Y-Mabs Therapeutics Inc Quarterly Revenue?

Y-Mabs Therapeutics Inc Quarterly Revenue rose 13.41% YoY to $26.5 M. Its sector's average revenue growth YoY for the quarter was 5.79%.

What is Y-Mabs Therapeutics Inc Quarterly Net profit?

Y-Mabs Therapeutics Inc Quarterly Net profit fell 587.25% YoY to $6.79 M. Its sector's average net profit growth YoY for the quarter was -41.98%.

What is Y-Mabs Therapeutics Inc Debt to Equity Ratio?

Y-Mabs Therapeutics Inc Debt to Equity Ratio of 0.01 is less than 1 and healthy. This implies that its assets are financed mainly through equity.

What is Y-Mabs Therapeutics Inc Return on Equity(ROE)?

Y-Mabs Therapeutics Inc Return on Equity(ROE) for the last financial year was -30.74%, less than 10%, indicating an inefficient use of shareholder's capital to generate profit.

What is Y-Mabs Therapeutics Inc Mutual Fund Holding?

Y-Mabs Therapeutics Inc Mutual Fund Holding decreased by 1.93% in the last quarter to 34.93.

What is Y-Mabs Therapeutics Inc Promoter Share Holding?

Y-Mabs Therapeutics Inc Promoter Share Holding increased by 0.44% in the most recent quarter to 1.61%.

What is Y-Mabs Therapeutics Inc Institutional Holding?

Y-Mabs Therapeutics Inc Institutional Holding increased by 0.01% in the last quarter to 57.44.

How is the Y-Mabs Therapeutics Inc today?

The Y-Mabs Therapeutics Inc today is trading in the green, up by 2.77% at 4.82.

How has Y-Mabs Therapeutics Inc performed historically?

The Y-Mabs Therapeutics Inc is currently trading up 2.77% on an intraday basis in the past week the index fell -0.21%. The index has been down -21.75% in the past quarter and fell -68.14% in the past year. You can view this in the overview section.

Y-Mabs Therapeutics Inc XNAS: YMAB

Y-Mabs Therapeutics Inc Live Share Price Today, Share Analysis and Chart

Name: Y-Mabs Therapeutics Inc: Is Infosys Ltd. worth buying?
Item: Y-Mabs Therapeutics Inc
Rating: 1.139597125
Author: Trendlyne DVM scores

Weak Stock

Download real time

4.82 0.13 (2.77%)

72.89% Fall from 52W High

141.8K XNAS Volume

XNAS 21 Apr, 2025 5:30 PM (EDT)

Y-Mabs Therapeutics Inc Key Metrics

My Metrics

Select

Market Capitalization Below industry Median Unavailable in chosen country	218
PE TTM Negative PE TTM Unavailable in chosen country	-7.3
PEG TTM High in industry Unavailable in chosen country	0.2
Price to Book Below industry Median Unavailable in chosen country	2.4
Institutional holding current Qtr % Below industry Median Unavailable in chosen country	57.4
Revenue Growth Qtr YoY % Below industry Median Unavailable in chosen country	13.4
Operating Revenue growth TTM % Below industry Median Unavailable in chosen country	3.4
Net Profit Qtr Growth YoY % Negative Net Profit Qtr Growth YoY % Unavailable in chosen country	-587.2
Net Profit TTM Growth % Negative Net Profit TTM Growth % Unavailable in chosen country	-38.5
Operating Profit Margin Qtr % Negative Operating Profit Margin Qtr % Unavailable in chosen country	-22.4
Operating Profit Margin TTM % Negative Operating Profit Margin TTM % Unavailable in chosen country	-35.6
Piotroski Score Below industry Median Unavailable in chosen country	3
Rel Perf vs Sector quarter% Unavailable in chosen country	-21.2
ROE Annual % Negative ROE Annual % Unavailable in chosen country	-30.7
RoA Annual % Negative RoA Annual % Unavailable in chosen country	-23.9

All financials are in USD Million and price data in USD

Low Financial Strength

22.2 / 100

Expensive Valuation

17.8 / 100

Technically Bearish

28.9 / 100

Weak Stock These stocks are the ones with poor quality, financials and technicals. This indicates that investors should be highly watchful with these stocks. View Similar Embed DVM

1Yr Price target upside is 253%

10 analysts

Check Before You Buy

Check P/E Buy Sell Zone

This stock has negative PE

Y-Mabs Therapeutics Inc Stock Price Analysis

Day Price Range 2.8% 1 Day return Unavailable in chosen country	4.8 (LTP) 4.64.9 LowHigh
Week Price Range -0.2% 1 Week return Unavailable in chosen country	4.8 (LTP) 4.55.4 LowHigh
Month Price Range -2.0% 1 Month return Unavailable in chosen country	4.8 (LTP) 3.95.4 LowHigh
52 Week Price Range -68.1% 1 Year return Unavailable in chosen country	4.8 (LTP) 3.917.8 LowHigh

View full Share Price History

Y-Mabs Therapeutics Inc Live Price Chart

Switch to TradingView

Fetching data ...

Forecaster - Analyst Share Price Target and Estimates

Consensus Recommendation

Forecaster is a Premium Feature

You need to upgrade your subscription plan to access this feature

Upgrade Now

Y-Mabs Therapeutics Inc Stock Analysis

Y-Mabs Therapeutics Inc stock analysis with key metrics, changes, and trends.

Y-Mabs Therapeutics Inc Metric	VALUE	CHANGE %	TREND	ANALYSIS
Annual Revenue	$87.68 M	3.38%	positive	Annual Revenue rose 3.38%, in the last year to $87.68 M. Its sector's average revenue growth for the last fiscal year was 7.49%.
Annual Net Profit	$29.67 M	38.45%	negative	Annual Net Profit fell 38.45% in the last year to $29.67 M. Its sector's average net profit growth for the last fiscal year was -32.44%.
Price to Earning Ratio	-7.35	-	negative	Price to Earning Ratio is -7.35, which is negative.
Stock Price	$4.82	-68.14%	negative	Stock Price fell 68.14% and underperformed its sector by 74.95% in the past year.
Quarterly Revenue	$26.5 M	13.41%	positive	Quarterly Revenue rose 13.41% YoY to $26.5 M. Its sector's average revenue growth YoY for the quarter was 5.79%.
Quarterly Net profit	$6.79 M	587.25%	negative	Quarterly Net profit fell 587.25% YoY to $6.79 M. Its sector's average net profit growth YoY for the quarter was -41.98%.
Debt to Equity Ratio	0.01	-	positive	Debt to Equity Ratio of 0.01 is less than 1 and healthy. This implies that its assets are financed mainly through equity.
Return on Equity(ROE)	-30.74 %	-30.74%	negative	Return on Equity(ROE) for the last financial year was -30.74%, less than 10%, indicating an inefficient use of shareholder's capital to generate profit.
Mutual Fund Holding	34.93 %	-1.93%	negative	Mutual Fund Holding decreased by 1.93% in the last quarter to 34.93.
Promoter Share Holding	1.61 %	0.44%	positive	Promoter Share Holding increased by 0.44% in the most recent quarter to 1.61%.
Institutional Holding	57.44 %	0.01%	positive	Institutional Holding increased by 0.01% in the last quarter to 57.44.

VIEW LESS

Loading data..

Y-Mabs Therapeutics Inc - Company Profile

What does Y-Mabs Therapeutics Inc do?

Y-mAbs Therapeutics Inc is a commercial-stage biopharmaceutical company. It is mainly engaged in the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer. DANYELZA, is the first FDA-approved product of the company which is a recombinant humanized immunoglobulin G, subtype 1k, or IgG1k, monoclonal antibody or mAb that targets ganglioside GD2, which is expressed in various neuroectoderm-derived tumors and sarcomas.

Gross Remuneration

2024

Gross Remuneration

Year

Y-Mabs Therapeutics Inc Live Share Price Today, Share Analysis and Chart

72.89% Fall from 52W High

Y-Mabs Therapeutics Inc Key Metrics

Market Capitalization

PE TTM

PEG TTM

Price to Book

Institutional holding current Qtr %

Revenue Growth Qtr YoY %

Operating Revenue growth TTM %

Net Profit Qtr Growth YoY %

Net Profit TTM Growth %

Operating Profit Margin Qtr %

Operating Profit Margin TTM %

Piotroski Score

Rel Perf vs Sector quarter%

ROE Annual %

RoA Annual %

SWOT Analysis

Check Before You Buy

Check P/E Buy Sell Zone

Y-Mabs Therapeutics Inc Stock Price Analysis

Day Price Range

Week Price Range

Month Price Range

52 Week Price Range

Y-Mabs Therapeutics Inc Live Price Chart

Forecaster - Analyst Share Price Target and Estimates

Revenue forecast

Consensus Recommendation

Y-Mabs Therapeutics Inc Stock Analysis

Y-Mabs Therapeutics Inc stock analysis with key metrics, changes, and trends.

Annual Revenue rose 3.38%, in the last year to $87.68 M. Its sector's average revenue growth for the last fiscal year was 7.49%.

Annual Net Profit fell 38.45% in the last year to $29.67 M. Its sector's average net profit growth for the last fiscal year was -32.44%.

Price to Earning Ratio is -7.35, which is negative.

Stock Price fell 68.14% and underperformed its sector by 74.95% in the past year.

Quarterly Revenue rose 13.41% YoY to $26.5 M. Its sector's average revenue growth YoY for the quarter was 5.79%.

Quarterly Net profit fell 587.25% YoY to $6.79 M. Its sector's average net profit growth YoY for the quarter was -41.98%.

Debt to Equity Ratio of 0.01 is less than 1 and healthy. This implies that its assets are financed mainly through equity.

Return on Equity(ROE) for the last financial year was -30.74%, less than 10%, indicating an inefficient use of shareholder's capital to generate profit.

Mutual Fund Holding decreased by 1.93% in the last quarter to 34.93.

Promoter Share Holding increased by 0.44% in the most recent quarter to 1.61%.

Institutional Holding increased by 0.01% in the last quarter to 57.44.

Y-Mabs Therapeutics Inc - Company Profile

What does Y-Mabs Therapeutics Inc do?

Y-Mabs Therapeutics Inc Management structure

Ms. Sue Smith

Senior Vice President and Chief Commercial Officer

Mr. Doug Gentilcore

Senior Vice President, Danyelza Business

Ms. Natalie Tucker

Senior Vice President, Radiopharmaceutical Business Head

Y-Mabs Therapeutics Inc Board of directors

Dr. Mary A. Tagliaferri, M.D.

Director

Dr. Gerard Ber, PhD

Independent Director

Mr. David N. Gill

Independent Director

Mr. Johan Wedell-Wedellsborg

Independent Director

Dr. James I. Healy, M.D.,PhD

Chairman of the Board

Ms. Laura J. Hamill

Independent Director

Y-Mabs Therapeutics Inc FAQ

How is Y-Mabs Therapeutics Inc today?

Y-Mabs Therapeutics Inc today is trading in the green, and is up by 2.77% at 4.82.

How has Y-Mabs Therapeutics Inc performed historically?

Y-Mabs Therapeutics Inc is currently trading up 2.77% on an intraday basis. In the past week the stock fell -0.21%. stock has been down -21.75% in the past quarter and fell -68.14% in the past year. You can view this in the overview section.